Craig R. Reinemeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Craig R. Reinemeyer has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Martin Krarup Nielsen
Department of Animal and Veterinary Sciences, Aarhus University, Tjele, Denmark
7 shared publications Alan A. Marchiondo
2 shared publicationsB. Schricker
Central Life Sciences, Phoenix, AZ, USA
2 shared publicationsEric C. Nichols
Teva Animal Health, Inc., 3915 South 48th Street Terrace, St. Joseph, MO 64503-4711, United States
2 shared publicationsJ.C. Prado
East Tennessee Clinical Research, 80 Copper Ridge Farm Road, Rockwood, TN 37854, USA
2 shared publicationsJulio C. Prado
East Tennessee Clinical Research, Inc., 80 Copper Ridge Farm Road, Rockwood, TN 37854, United States
2 shared publications
Latest Publications
- Open Access
- 6 April 2026
- Published by Springer Nature in Parasites & Vectors
- Vol. 19 (1)
Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs
Background: Canine heartworm ( Dirofilaria immitis ), a filarial parasite endemic in many countries worldwide, can cause life-threatening disease in dogs if left untreated. Two laboratory studies and one field study were conducted to evaluate the efficacy of Credelio Quattro, a novel chewable tablet containing moxidectin in combination with lotilaner, praziquantel and pyrantel, for the prevention of heartworm disease caused by D. immitis . Methods: In the laboratory studies, dogs were inoculated with 50 D. immitis L3 larvae on Day – 30. Eight dogs per group were randomized to receive either a placebo or Credelio Quattro at the minimum effective dosage of 0.02 mg/kg moxidectin, 20 mg/kg lotilaner, 5 mg/kg praziquantel, and 5 mg/kg pyrantel on Day 0. One of the studies also included a lotilaner-only treated group to demonstrate non-interference. Efficacy was evaluated ~ 150 days post-inoculation utilizing adult heartworm counts collected at necropsy. The field study enrolled client-owned dogs, ≥ 8 eight weeks of age, weighing at least 1.5 kg, from 13 geographically diverse veterinary clinics throughout the USA. Dogs were randomized in a 1:1 ratio to receive either Credelio Quattro or a positive control product, Simparica Trio ® (moxidectin/sarolaner/pyrantel), at the recommended label dosages for 11 consecutive months. Efficacy was evaluated on Day 330 by assessing the detection of adult heartworm infections using antigen and microfilarial tests. Results: In both laboratory studies, no adult heartworms were collected from any of the dogs treated with a single dose of Credelio Quattro. In contrast, all dogs treated with placebo (range 13–40) or lotilaner-only (range 9–42) had adults present. A total of 372 dogs were enrolled in the field study (191 Credelio Quattro, 181 Simparica Trio). At the end of the study, no dogs from either treatment group tested positive for adult heartworms. Credelio Quattro was well tolerated in all studies. Conclusions: The laboratory studies demonstrated Credelio Quattro as 100% effective for the prevention of heartworm disease caused by D. immitis in dogs. Additionally, no dogs in the field study tested positive for adult heartworm infection after 11 consecutive monthly doses of Credelio Quattro. Graphical
- 6 April 2026
- Published by Springer Nature in Parasites & Vectors
- Vol. 19 (1)
Open AccessEfficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs
Background: Canine heartworm ( Dirofilaria immitis ), a filarial parasite endemic in many countries worldwide, can cause life-threatening disease in dogs if left untreated. Two laboratory studies and one field study were conducted to evaluate the efficacy of Credelio Quattro, a novel chewable tablet containing moxidectin in combination with lotilaner, praziquantel and pyrantel, for the prevention of heartworm disease caused by D. immitis . Methods: In the laboratory studies, dogs were inoculated with 50 D. immitis L3 larvae on Day – 30. Eight dogs per group were randomized to receive either a placebo or Credelio Quattro at the minimum effective dosage of 0.02 mg/kg moxidectin, 20 mg/kg lotilaner, 5 mg/kg praziquantel, and 5 mg/kg pyrantel on Day 0. One of the studies also included a lotilaner-only treated group to demonstrate non-interference. Efficacy was evaluated ~ 150 days post-inoculation utilizing adult heartworm counts collected at necropsy. The field study enrolled client-owned dogs, ≥ 8 eight weeks of age, weighing at least 1.5 kg, from 13 geographically diverse veterinary clinics throughout the USA. Dogs were randomized in a 1:1 ratio to receive either Credelio Quattro or a positive control product, Simparica Trio ® (moxidectin/sarolaner/pyrantel), at the recommended label dosages for 11 consecutive months. Efficacy was evaluated on Day 330 by assessing the detection of adult heartworm infections using antigen and microfilarial tests. Results: In both laboratory studies, no adult heartworms were collected from any of the dogs treated with a single dose of Credelio Quattro. In contrast, all dogs treated with placebo (range 13–40) or lotilaner-only (range 9–42) had adults present. A total of 372 dogs were enrolled in the field study (191 Credelio Quattro, 181 Simparica Trio). At the end of the study, no dogs from either treatment group tested positive for adult heartworms. Credelio Quattro was well tolerated in all studies. Conclusions: The laboratory studies demonstrated Credelio Quattro as 100% effective for the prevention of heartworm disease caused by D. immitis in dogs. Additionally, no dogs in the field study tested positive for adult heartworm infection after 11 consecutive monthly doses of Credelio Quattro. Graphical
- Open Access
- 1 March 2020
- Published by Springer Nature in Parasites & Vectors
- Vol. 13 (1) , 1-8
Efficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced ascarid infections in dogs
Background: Ascarid infections are among the most prevalent intestinal parasitic infections occurring in dogs around the world, with Toxocara canis and Toxascaris leonina commonly observed. Toxocara canis can cause considerable disease in dogs and humans, and year-round prophylactic treatment and control in dogs is recommended. Elimination of immature stages of these parasites before egg-laying will reduce environmental contamination and the risk of infection for both dogs and humans. Studies were conducted to evaluate the efficacy of a novel, oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced immature adult (L5) and adult T. canis, and adult T. leonina infections in dogs. Methods: Six negative-controlled, masked, randomized laboratory studies were conducted. Two studies each evaluated efficacy against immature adult (L5) T. canis, adult T. canis, and adult T. leonina. Sixteen to 40 dogs were included in each study. Dogs experimentally infected with the target parasite were dosed once on Day 0 with either placebo tablets or Simparica Trio™ tablets to provide minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5.0 mg/kg pyrantel (as pamoate salt). Efficacy was based on the number of worms recovered at necropsy 7–10 days after treatment compared to placebo control. Results: Based on geometric mean worm counts, efficacy of the sarolaner + moxidectin + pyrantel combination was ≥ 95.2% against immature adult T. canis, ≥ 97.3% against adult T. canis, and ≥ 89.7% against adult T. leonina. There were no treatment-related adverse events in any study. Conclusions: These studies confirm the efficacy of a single dose of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against immature adult and adult T. canis, and adult T. leonina infections in dogs.
- 1 March 2020
- Published by Springer Nature in Parasites & Vectors
- Vol. 13 (1) , 1-8
Open AccessEfficacy of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced ascarid infections in dogs
Background: Ascarid infections are among the most prevalent intestinal parasitic infections occurring in dogs around the world, with Toxocara canis and Toxascaris leonina commonly observed. Toxocara canis can cause considerable disease in dogs and humans, and year-round prophylactic treatment and control in dogs is recommended. Elimination of immature stages of these parasites before egg-laying will reduce environmental contamination and the risk of infection for both dogs and humans. Studies were conducted to evaluate the efficacy of a novel, oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against induced immature adult (L5) and adult T. canis, and adult T. leonina infections in dogs. Methods: Six negative-controlled, masked, randomized laboratory studies were conducted. Two studies each evaluated efficacy against immature adult (L5) T. canis, adult T. canis, and adult T. leonina. Sixteen to 40 dogs were included in each study. Dogs experimentally infected with the target parasite were dosed once on Day 0 with either placebo tablets or Simparica Trio™ tablets to provide minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5.0 mg/kg pyrantel (as pamoate salt). Efficacy was based on the number of worms recovered at necropsy 7–10 days after treatment compared to placebo control. Results: Based on geometric mean worm counts, efficacy of the sarolaner + moxidectin + pyrantel combination was ≥ 95.2% against immature adult T. canis, ≥ 97.3% against adult T. canis, and ≥ 89.7% against adult T. leonina. There were no treatment-related adverse events in any study. Conclusions: These studies confirm the efficacy of a single dose of a new oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against immature adult and adult T. canis, and adult T. leonina infections in dogs.
- 1 April 2019
- Published by Elsevier in Veterinary Parasitology
- Vol. 268, 53-60
A model for the dynamics of the parasitic stages of equine cyathostomins
- 1 April 2019
- Published by Elsevier in Veterinary Parasitology
- Vol. 268, 53-60
A model for the dynamics of the parasitic stages of equine cyathostomins
- 1 July 2016
- Published by Elsevier in Veterinary Parasitology
- Vol. 225, 117-122
Efficacy of oral afoxolaner plus milbemycin oxime chewables against induced gastrointestinal nematode infections in dogs
- 1 July 2016
- Published by Elsevier in Veterinary Parasitology
- Vol. 225, 117-122
Efficacy of oral afoxolaner plus milbemycin oxime chewables against induced gastrointestinal nematode infections in dogs
- 12 January 2016
- Published by Wiley in Equine Veterinary Education
- Vol. 29 (4) , 225-232
Control of helminth parasites in juvenile horses
Summary: Parasite control in juvenile horses remains a substantial challenge for veterinary practitioners and their clients. This age group is at risk for various types of parasitic disease because their worm burdens tend to be larger and more diverse than in mature horses. This contrast is largely attributable to marked differences in relative levels of acquired immunity. Frequent, perennial anthelmintic treatment is not a sustainable approach for parasite control in this age group, but the simple, surveillance‐based parasite control strategies recommended for mature horses are not appropriate for juveniles either. Maneuvering through the early years of a horse's life requires up‐to‐date knowledge about biology and epidemiology of the parasite species in play as well as local evidence regarding the anthelmintic resistance status of each herd. This article provides an overview of the most important helminth parasites to target in a control programme for juvenile horses, and highlights how the target species change as horses age. Young foals (Strongyloides westeri and Parascaris spp., whereas the primary target parasite in foals between age 2 months and weaning is Parascaris spp. Beyond weaning, the focus shifts away from ascarids, and the targets instead are strongyles and tapeworms. Gasterophilus spp. and Oxyuris equi are also discussed.
- 12 January 2016
- Published by Wiley in Equine Veterinary Education
- Vol. 29 (4) , 225-232
Control of helminth parasites in juvenile horses
Summary: Parasite control in juvenile horses remains a substantial challenge for veterinary practitioners and their clients. This age group is at risk for various types of parasitic disease because their worm burdens tend to be larger and more diverse than in mature horses. This contrast is largely attributable to marked differences in relative levels of acquired immunity. Frequent, perennial anthelmintic treatment is not a sustainable approach for parasite control in this age group, but the simple, surveillance‐based parasite control strategies recommended for mature horses are not appropriate for juveniles either. Maneuvering through the early years of a horse's life requires up‐to‐date knowledge about biology and epidemiology of the parasite species in play as well as local evidence regarding the anthelmintic resistance status of each herd. This article provides an overview of the most important helminth parasites to target in a control programme for juvenile horses, and highlights how the target species change as horses age. Young foals (Strongyloides westeri and Parascaris spp., whereas the primary target parasite in foals between age 2 months and weaning is Parascaris spp. Beyond weaning, the focus shifts away from ascarids, and the targets instead are strongyles and tapeworms. Gasterophilus spp. and Oxyuris equi are also discussed.
- 21 October 2015
- Published by Elsevier in Veterinary Parasitology
- Vol. 214 (1-2) , 100-107
Comparison of the larvicidal efficacies of moxidectin or a five-day regimen of fenbendazole in horses harboring cyathostomin populations resistant to the adulticidal dosage of fenbendazole
- 21 October 2015
- Published by Elsevier in Veterinary Parasitology
- Vol. 214 (1-2) , 100-107
Comparison of the larvicidal efficacies of moxidectin or a five-day regimen of fenbendazole in horses harboring cyathostomin populations resistant to the adulticidal dosage of fenbendazole
- 7 August 2014
- Published by Wiley in Equine Veterinary Education
- Vol. 26 (11) , 584-591
Review of the biology and control of O xyuris equi
Summary: O xyuris equi is a well‐known equine parasite that has evolved over time from an easily controlled, minor nuisance into an increasingly prevalent pest that may frustrate even the most intensive management efforts. This paper reviews essential features of the biology, epidemiology, pathology, diagnosis and control of O xyuris infections, and describes the current status of recent biological adaptations.
- 7 August 2014
- Published by Wiley in Equine Veterinary Education
- Vol. 26 (11) , 584-591
Review of the biology and control of O xyuris equi
Summary: O xyuris equi is a well‐known equine parasite that has evolved over time from an easily controlled, minor nuisance into an increasingly prevalent pest that may frustrate even the most intensive management efforts. This paper reviews essential features of the biology, epidemiology, pathology, diagnosis and control of O xyuris infections, and describes the current status of recent biological adaptations.
- 1 August 2014
- Published by Elsevier in Veterinary Parasitology
- Vol. 204 (3-4) , 229-237
Effects of daily pyrantel tartrate on strongylid population dynamics and performance parameters of young horses repeatedly infected with cyathostomins and Strongylus vulgaris
- 1 August 2014
- Published by Elsevier in Veterinary Parasitology
- Vol. 204 (3-4) , 229-237
Effects of daily pyrantel tartrate on strongylid population dynamics and performance parameters of young horses repeatedly infected with cyathostomins and Strongylus vulgaris
- 1 July 2014
- Published by Elsevier in Veterinary Parasitology
- Vol. 204 (1-2) , 34-43
Herding the U.S. cattle industry toward a paradigm shift in parasite control
- 1 July 2014
- Published by Elsevier in Veterinary Parasitology
- Vol. 204 (1-2) , 34-43
Herding the U.S. cattle industry toward a paradigm shift in parasite control
- Open Access
- 4 April 2013
- Published by Springer Nature in Parasites & Vectors
- Vol. 6 (1) , 84
SvSXP: a Strongylus vulgaris antigen with potential for prepatent diagnosis
Strongyle parasites are ubiquitous in grazing horses. Strongylus vulgaris, the most pathogenic of the large strongyles, is known for its extensive migration in the mesenteric arterial system. The lifecycle of S. vulgaris is characterised by a long prepatent period where the migrating larvae are virtually undetectable as there currently is no test available for diagnosing prepatent S. vulgaris infection. Presence of S. vulgaris larvae in the arterial system causes endarteritis and thrombosis with a risk of non-strangulating intestinal infarctions. Emergence of anthelmintic resistance among cyathostomins has led to recommendations of reduced treatment intensity by targeting horses that exceed a predetermined strongyle faecal egg count threshold. One study suggests an apparent increase in prevalence of S. vulgaris on farms where reduced anthelmintic treatment intensity has been implemented. These issues highlight the need for an accurate and reliable assay for diagnosing prepatent S. vulgaris infection.
- 4 April 2013
- Published by Springer Nature in Parasites & Vectors
- Vol. 6 (1) , 84
Open AccessSvSXP: a Strongylus vulgaris antigen with potential for prepatent diagnosis
Strongyle parasites are ubiquitous in grazing horses. Strongylus vulgaris, the most pathogenic of the large strongyles, is known for its extensive migration in the mesenteric arterial system. The lifecycle of S. vulgaris is characterised by a long prepatent period where the migrating larvae are virtually undetectable as there currently is no test available for diagnosing prepatent S. vulgaris infection. Presence of S. vulgaris larvae in the arterial system causes endarteritis and thrombosis with a risk of non-strangulating intestinal infarctions. Emergence of anthelmintic resistance among cyathostomins has led to recommendations of reduced treatment intensity by targeting horses that exceed a predetermined strongyle faecal egg count threshold. One study suggests an apparent increase in prevalence of S. vulgaris on farms where reduced anthelmintic treatment intensity has been implemented. These issues highlight the need for an accurate and reliable assay for diagnosing prepatent S. vulgaris infection.